Theres also a risk that the excitement about these new medications might overshadow crucial public health efforts focused on prevention and lifestyle changes.[6] This practice not only contravenes regulatory standards, but also erodes public trust in the pharmaceutical industry
To view or add a comment, sign in SELECT (NEJM 2023): semaglutide cut major cardiovascular events 20% in obese patients WITHOUT diabetes the first obesity drug to reduce hard CV endpoints
This suggests that the parasitized erythrocyte becomes mildly oxidizing upon infection
GSH12 60 250mg500mg 2
Other groups of people who have a higher risk include people over age 60, people on certain medications for diabetes, people with Crohns disease, celiac, ulcerative colitis and irritable bowel syndrome and women with a history of infertility or miscarriage
These results are likely due to reductions in inflammation, improved blood pressure control, and lower body weight achieved while taking the medication
